Satellos Bioscience
MSLE
30 hedge funds and large institutions have $64.7M invested in Satellos Bioscience in 2026 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
37% more capital inflows, than outflows
Capital inflows: $5.37M | Capital outflows: $3.93M
15% more funds holding
Funds holding: 26 → 30 (+4)
0.06% more ownership
Funds ownership: 36.89% → 36.95% (+0.06%)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$1.55M |
| 2 |
6CM
683 Capital Management
New York
|
+$1.16M |
| 3 |
Millennium Management
New York
|
+$941K |
| 4 |
CRCM LP
San Francisco,
California
|
+$634K |
| 5 |
Quadrature Capital
London,
United Kingdom
|
+$362K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avidity Partners Management
Dallas,
Texas
|
-$2.08M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$466K |
| 3 |
Empery Asset Management
New York
|
-$457K |
| 4 |
Stonepine Capital Management
Bend,
Oregon
|
-$341K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$229K |
MSLE Hedge Fund Activity: Q3 2026 in Review
30 of the 8,167 institutional investors tracked by Wall St. Rank reported a position in Satellos Bioscience (MSLE) for Q3 2026, worth a combined $64.7M — up 8.7% from $59.6M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new MSLE positions and 2 closed out — a net gain of 4 holders — while 6 added to existing stakes and 10 trimmed.
The largest buyer was Saturn V Capital Management, adding an estimated $1.55M. The largest seller was Avidity Partners Management, cutting an estimated $2.08M.
- 30 institutional investors held Satellos Bioscience (MSLE) as of Q3 2026, up from 26 in Q2 2026.
- Funds reported $64.7M of Satellos Bioscience stock for Q3 2026, up 8.7% quarter-over-quarter.
- 6 funds opened new Satellos Bioscience positions in Q3 2026 and 2 closed out, a net change of +4 holders.
- The largest Satellos Bioscience buyer in Q3 2026 was Saturn V Capital Management, an estimated $1.55M added.
- The largest Satellos Bioscience seller in Q3 2026 was Avidity Partners Management, an estimated $2.08M sold.
Based on aggregated 13F filings for Q3 2026.